Literature DB >> 8889464

Treatment of colitis in Behçet's disease with thalidomide.

P T Postema1, P den Haan, P M van Hagen, M van Blankenstein.   

Abstract

A 40-year-old Turkish man on busulphan treatment for chronic myeloid leukaemia was hospitalized with steroid resistant (up to 100 mg prednisolone/24 h for over 4 weeks) colitis. On the basis of concomitant orogenital ulceration and unusual, deep punched out ulcers in the colon and smaller ulcers in the terminal ileum, Behçet's disease of the bowel, manifesting as ileocolitis, was diagnosed. Leukaemic infiltration, Crohn's colitis, neutropenic colitis and infectious colitis were excluded by histology and cultures. Treatment with colchicine 2 mg/day improved the orogenital ulcers but with only minor improvement of the colitis. Thalidomide treatment (400 mg/day), however, dramatically improved the colitis within 7 days: fever and diarrhoea disappearing. Colonoscopy after 4 weeks of treatment revealed previously giant ulcers practically healed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8889464

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  8 in total

Review 1.  Small therapeutic molecules for the treatment of inflammatory bowel disease.

Authors:  S J H van Deventer
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

Review 2.  Update on the therapy of Behçet disease.

Authors:  Zeinab Saleh; Thurayya Arayssi
Journal:  Ther Adv Chronic Dis       Date:  2014-05       Impact factor: 5.091

Review 3.  Gastrointestinal Behçet's disease: a review.

Authors:  Wasseem Skef; Matthew J Hamilton; Thurayya Arayssi
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

4.  Panuveitis simulating ocular Behçet's in cases of chronic myelogenous leukaemia in remission.

Authors:  Rohan Chawla; Koushik Tripathy
Journal:  BMJ Case Rep       Date:  2017-11-23

5.  Recurrent ECSIT mutation encoding V140A triggers hyperinflammation and promotes hemophagocytic syndrome in extranodal NK/T cell lymphoma.

Authors:  Haijun Wen; Huajuan Ma; Qichun Cai; Suxia Lin; Xinxing Lei; Bin He; Sijin Wu; Zifeng Wang; Yan Gao; Wensheng Liu; Weiping Liu; Qian Tao; Zijie Long; Min Yan; Dali Li; Keith W Kelley; Yongliang Yang; Huiqiang Huang; Quentin Liu
Journal:  Nat Med       Date:  2018-01-01       Impact factor: 53.440

Review 6.  Thalidomide and derivatives: immunological investigations of tumour necrosis factor-alpha (TNF-alpha) inhibition suggest drugs capable of selective gene regulation.

Authors:  S M McHugh; T L Rowland
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

Review 7.  Thalidomide in cancer treatment: a potential role in the elderly?

Authors:  Shufeng Zhou; Philip Kestell; Malcolm D Tingle; James W Paxton
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

8.  Efficacy of Adalimumab in a Girl with Refractory Intestinal Behcet's Disease.

Authors:  Mariko Kaji; Takayuki Kishi; Takako Miyamae; Satoru Nagata; Hisashi Yamanaka; Satoshi Fujikawa
Journal:  Case Rep Rheumatol       Date:  2015-11-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.